Naringenin has been shown to decrease the infiltration of MDSCs and Treg cells in breast cancer cell lines, and to upregulate IL-2 and INF-γ -releasing T cells in spleen and lung tissue, demonstrating its use as an immunomodulatory agent. Here, IL2 is linked to breast cancer.